De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma.

Teisseire M, Sahu U, Parola J, Tsai MC, Vial V, Durivault J, Grépin R, Cormerais Y, Molina C, Gouraud A, Pagès G, Ben-Sahra I, Giuliano S

Open source

DOI: 10.1158/0008-5472.can-24-1393
Published: 2025 May 15
Container: Cancer research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/0008-5472.can-24-1393,
  title = {De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma.},
  author = {Teisseire M and Sahu U and Parola J and Tsai MC and Vial V and Durivault J and Grépin R and Cormerais Y and Molina C and Gouraud A and Pagès G and Ben-Sahra I and Giuliano S},
  year = {2025},
  journal = {Cancer research},
  doi = {10.1158/0008-5472.can-24-1393},
  url = {https://doi.org/10.1158/0008-5472.can-24-1393}
}

RIS

TY  - JOUR
TI  - De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma.
AU  - Teisseire M
AU  - Sahu U
AU  - Parola J
AU  - Tsai MC
AU  - Vial V
AU  - Durivault J
AU  - Grépin R
AU  - Cormerais Y
AU  - Molina C
AU  - Gouraud A
AU  - Pagès G
AU  - Ben-Sahra I
AU  - Giuliano S
PY  - 2025
JO  - Cancer research
DO  - 10.1158/0008-5472.can-24-1393
UR  - https://doi.org/10.1158/0008-5472.can-24-1393
ER  -

APA

M, T., U, S., J, P., MC, T., V, V., J, D., R, G., Y, C., C, M., A, G., G, P., I, B., & S, G. (2025). De Novo Serine Synthesis Is a Metabolic Vulnerability That Can Be Exploited to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma.. Cancer research. https://doi.org/10.1158/0008-5472.can-24-1393

Source records

pubmed · retrieved 2026-09-26T15:58:03.609Z